Abbott announced on Friday that The FDA provided emergency authorization for a fast coronavirus testing Platform for the detection of a novel coronavirus (COVID-19), which provides positive results in just 5 minutes and negative results in 13 minutes.
Abbott will provide healthcare staff with 50,000 COVID-19 tests every day starting on Wednesday, using its updated ID NOW testing process, he said. Bringing fast testing capacity for coronavirus to the front medical lines is essential in the fight to compress the growing curve infections and deaths around the world.
The test will run on the current ID NOW platform of the company that will deliver fast results in a wide variety of healthcare conditions, such as offices for doctors, emergency care centers, and emergency departments for hospitals. The Fast coronavirus testing Platform weighs around 6.6 pounds and is the size of a small toaster.
During a press conference on Sunday, President Donald Trump unveiled the fast coronavirus testing Platform, adding that the Food and Drug Administration authorized the test in four weeks while It takes ten months to get a standard approval procedure.
ID NOW employs molecular technology that offers a high level of accuracy, the Abbott said. Today Abbott’s ID NOW is the most widely available molecular point-of-care research testing platform in the United States.
“The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Abbott’s President Robert B. Ford. “With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”
Successful Results Promised with Fast coronavirus testing Platform
Abbott will make available ID NOW COVID-19 assessments to healthcare providers in emergency care facilities in the U.S., where most ID NOW instruments are currently in use. The company is collaborating with the Trump administration to implement experiments in places where they can have the most excellent effect.
The introduction of the Abbott ID NOW COVID-19 test (Fast coronavirus testing Platform) comes a week after the company’s “Abbott m2000” “RealTime SARS-CoV-2 EUA” test, which performs in hospital and reference laboratories around the world on the “m2000 RealTime” system. Abbott expects to deliver approximately 5 million tests a month between the two platforms.
Monitoring is crucial to combating the pandemic, Abbott said, and using emerging technology to help mitigate the spread of the virus is a top priority for public health authorities and healthcare professionals.
Leveling the Curve
In 2014, Abbott launched the ID NOW molecular point-of-care testing platform for Influenza A & B, Strep A and RSV monitoring in the U.S. It is a fast, instrument-based, isothermal device designed to detect infectious diseases qualitatively.
Its innovative technology to amplify isothermal nucleic acid produces molecular results in just minutes. Obtaining these timely tests allows doctors to make treatment decisions based on facts during a hospital visit.
The combination of its testing abilities ID NOW and m2000 COVID-19 (Fast coronavirus testing Platform) will provide about 5 million tests per month. Abbott is also working on a rapid antibody test to identify coronavirus-infected patients, reports claim. Perhaps the most important thing right now is extensive research, noted Arle Lommel, a senior analyst at CSA Research.
It’s still unclear how many people are currently affected by COVID-19. Data continues to grow, he explained, that many people have’ asymptomatic. “The challenge here is that the appropriate response will be very different depending on what percentage of the populace will require care,”
On the other side, if extensive research shows less frequent than suspected asymptomatic carriers, we will need to take much more drastic steps. The rate of fatality would be higher, and the size of the curve to flatten would be more significant than expected, he added.
Another Potential to defeat the disease
A fast test of an antibody is an exciting opportunity to protect against uncontrolled disease. Pinar Keskinocak, president of the Institute for Operations Research and the Management Sciences and professor at the Georgia Institute of Technology, observed that such a study, if widely available, could identify previously infected and recovered individuals and further improve our understanding about of spread. He Said that “These individuals are most likely to have partial immunity to the disease and could return to work, following certain precautionary guidelines,”
Even without the accelerated antibody test, Abbott’s Fast coronavirus testing Platform and speedy COVID-19 research platform will be handy in flattening the infection curve, Keskinocak added. This will allow for rapid medical intervention, as well as a clearer understanding of the location and severity of current infections. This will also boost prediction accuracy on how the disease is likely to spread geographically and over time.
“We have been trying to put out a fire without seeing where the fire was, how big it was and how fast it has been spreading,” said Keskinocak, who is an expert in modeling and testing prevention methods for infectious diseases. “The circumstance is like flying over a thick fog filled area. Now the fog is about to clear, providing significantly better visibility to mobilize support and target efforts to respond”, she said.
Further Perspectives with Fast coronavirus testing Platform
According to Erika Gray, Pharm.D, co-founder of Toolbox Genomics, Abbott’s ID NOW program will help knock down the greatest obstacle to research performance, which is turnaround time. The pace at which COVID-19 is detected or confirmed is critical. She Said that “Many hospitals do not know if a patient is positive for two or three days because of the testing backlog. As a result, the patient has to be treated as a high-risk patient with high resource needs until the test comes back.”
The opportunity to monitor potentially patients in the field is an even more critical factor of the rapid testing processes. Gray said, “I’m not sure if this is possible, but ambulance [staff] might be able to carry this test with them and test people in the field. EMTs can test glucose in the field.”
Urgent Search for Asymptomatic Cases
Abbott’s Fast coronavirus testing Platform would also add a new level of fast treatment to people who lack symptoms and remain broad for the disease to spread. Drive-through testing centers and emergency departments would be able to quickly produce tests, speeding up patient care and medical treatment.
Urban areas need to be able to randomly check their populations instead of applying tests to people who have such symptoms. Point-of-care testing could turn that into practice. “We know the majority of people with the virus are asymptomatic, but only people with COVID-19 symptoms are being given access to the test,” Gray said. “Rapid point-of-care testing is very important.”
What Does now we need to do?
Asymptomatic testing is essential, Gray stressed. Two weeks later, asymptomatic people who test positive require a follow-up test to confirm that they are no longer have the coronavirus. “It may be worth doing serial re-testing to ensure people do not contract the virus again. We don’t know how this virus behaves, as it is novel, and we don’t know if people can be re-infected,” she clarified.
As the longer-term, Lommel urged that both immunization services and investigation into the best treatment for victims are required. Even with wide-ranging monitoring, COVID-19 is likely to continue to exist in the background at deficient levels, concealed in the noise of “flu-like diseases,” which are never reported.
Furthermore, we need to know the precision of the Abbott ID NOW (Fast coronavirus testing Platform). There could be a deficient false-negative score. When it says somebody is disease-free, then we need to be reasonably confident that this is valid. Perhaps people who are affected will carry on infecting others.